2012
Opioid Detoxification and Naltrexone Induction Strategies: Recommendations for Clinical Practice
Sigmon SC, Bisaga A, Nunes EV, O'Connor PG, Kosten T, Woody G. Opioid Detoxification and Naltrexone Induction Strategies: Recommendations for Clinical Practice. The American Journal Of Drug And Alcohol Abuse 2012, 38: 187-199. PMID: 22404717, PMCID: PMC4331107, DOI: 10.3109/00952990.2011.653426.Peer-Reviewed Original ResearchConceptsΜ-opioid receptor antagonist naltrexoneSignificant public health problemDose of buprenorphinePublic health problemLevel of careOral naltrexoneOpioid detoxificationAntagonist naltrexoneOpioid dependencePatient selectionOpioid agonistsAgonist maintenanceAncillary medicationsFavorable outcomeHigh riskTarget doseClinical practiceHealth problemsNaltrexoneExpert cliniciansTreatmentDoseMore researchUseful alternativeBest approach
2008
Substance Abuse and Withdrawal in the Critical Care Setting
Tetrault JM, O'Connor PG. Substance Abuse and Withdrawal in the Critical Care Setting. Critical Care Clinics 2008, 24: 767-788. PMID: 18929942, DOI: 10.1016/j.ccc.2008.05.005.Commentaries, Editorials and LettersConceptsCritical care settingWithdrawal syndromeCare settingsOverall treatment protocolSubstance useSubstance withdrawal syndromeSymptom-triggered approachCritical care teamTapering doseAcute presentationResuscitative measuresCare teamTreatment protocolHigh indexSubstance intoxicationSubstance abuseAbused drugsSyndromeTreatmentWithdrawalEpidemiologySettingSuspicionDoseIntoxication
2005
Buprenorphine tablet versus liquid: A clinical trial comparing plasma levels, efficacy, and symptoms
Chawarski MC, Moody DE, Pakes J, O'Connor PG, Schottenfeld RS. Buprenorphine tablet versus liquid: A clinical trial comparing plasma levels, efficacy, and symptoms. Journal Of Substance Use And Addiction Treatment 2005, 29: 307-312. PMID: 16311183, DOI: 10.1016/j.jsat.2005.08.011.Peer-Reviewed Original ResearchConceptsTrough concentrationsPlasma concentrationsOpiate-dependent volunteersIllicit opioid usePeak plasma concentrationBuprenorphine doseBuprenorphine tabletsOpioid useWithdrawal symptomsBuprenorphine levelsPlasma levelsTablet doseClinical trialsLarge intersubjectLiquid formulationStudy participantsIntrasubject variabilityPlasma samplesPeak concentrationTablet formulationLiquid dosesDays of maintenanceSymptomsDoseConcentration curve
1997
Treatment of Early AIDS Dementia in Intravenous Drug Users: High Versus Low Dose Peptide T
Kosten T, Rosen M, McMahon T, Bridge T, O'malley S, Pearsall R, O'connor P. Treatment of Early AIDS Dementia in Intravenous Drug Users: High Versus Low Dose Peptide T. The American Journal Of Drug And Alcohol Abuse 1997, 23: 543-553. PMID: 9366972, DOI: 10.3109/00952999709016894.Peer-Reviewed Original Research